Jason Zhang

US Patent:

20050009843, Jan 13, 2005

Filed:

Apr 24, 2002

Appl. No.:

10/475091

Inventors:

Kiyoshi Nakayama - Tokyo, JP
Masami Ohtsuka - Tokyo, JP
Haruko Kawato - Tokyo, JP
Ryo Okumura - Tokyo, JP
Kazuki Hoshino - Tokyo, JP
William Watkins - Waltham MA, US
Jason Zhang - Waltham MA, US
Monica Palme - Waltham MA, US
Aesop Cho - Waltham MA, US

International Classification:

A61K031/519

US Classification:

514259410

Abstract:

A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): wherein, Rand Rrepresent hydrogen atom, a halogen atom, hydroxyl group or the like, Wrepresents —CH═CH—, —CHO—, —CHCH— or the like; Rrepresents hydrogen atom, a halogen atom, hydroxyl group or an amino group; Rrepresents hydrogen atom, a group of —OZR(Zrepresents an alkylene group, a fluorine-substituted alkylene group or a single bond, and Rrepresents a cyclic alkyl group, an aryl group or the like); Wrepresents a single bond or —C(R)═C(R)—(Rand Rrepresent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but Wand Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.

US Patent:

20210032620, Feb 4, 2021

Filed:

Aug 7, 2018

Appl. No.:

16/636902

Inventors:

- Singapore, SG
Zhong Zhong - Hingham MA, US
Naoki Iwamoto - Brighton MA, US
Jason Jingxin Zhang - Walpole MA, US
Jean-Cosme Dodart - Boston MA, US
Yuanjing Liu - Arlington MA, US
Pachamuthu Kandasamy - Belmont MA, US
Sethumadhavan Divakaramenon - Lexington MA, US
Genliang Lu - Winchester MA, US
Subramanian Marappan - Acton MA, US

International Classification:

C12N 15/11

Abstract:

Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in treatment of C9orf72-related disorders.

US Patent:

20200362337, Nov 19, 2020

Filed:

Aug 7, 2018

Appl. No.:

16/636900

Inventors:

- Singapore, SG
Yuanjing Liu - Arlington MA, US
Chandra Vargeese - Schwenksville PA, US
Zhong Zhong - Hingham MA, US
Naoki Iwamoto - Brighton MA, US
Jason Jingxin Zhang - Walpole MA, US
Pachamuthu Kandasamy - Belmont MA, US
Sethumadhavan Divakaramenon - Lexington MA, US
Genliang Lu - Winchester MA, US
Subramanian Marappan - Acton MA, US

International Classification:

C12N 15/113

Abstract:

Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in treatment of C9orf72-related disorders.

US Patent:

20200190515, Jun 18, 2020

Filed:

Jun 1, 2018

Appl. No.:

16/618001

Inventors:

- Singapore, SG
- New York NY, US
David Charles Donnell Butler - Medford MA, US
Subramanian Marappan - Acton MA, US
Genliang Lu - Winchester MA, US
Jason Jingxin Zhang - Walpole MA, US
Vinod Vathipadiekal - Stoneham MA, US
Luciano Henrique Apponi - Chelsea MA, US
Hanna Maria Wisniewska - Providence RI, US
Xiayun Cheng - Old Saybrook CT, US
Young Jin Cho - Belmont MA, US

International Classification:

C12N 15/113
A61K 45/06
A61K 47/54
A61K 47/55

Abstract:

Among other things, the present disclosure provides designed PNPLA3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in RNA interference and/or RNase H-mediated knockdown.

US Patent:

20200157545, May 21, 2020

Filed:

Jun 1, 2018

Appl. No.:

16/618010

Inventors:

Chandra VARGEESE - Cambridge MA, US
Naoki IWAMOTO - Cambridge MA, US
David Charles Donnell BUTLER - Cambridge MA, US
Subramanian MARAPPAN - Cambridge MA, US
Genliang LU - Cambridge MA, US
Jason Jingxin ZHANG - Cambridge MA, US
Vinod VATHIPADIEKAL - Cambridge MA, US
Luciano Henrique APPONI - Cambridge MA, US
- Singapore, SG

Assignee:

WAVE LIFE SCIENCES LTD. - Singapore

International Classification:

C12N 15/113
A61K 31/712

Abstract:

Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in RNA interference and/or RNase H-mediated knockdown.

US Patent:

20190390197, Dec 26, 2019

Filed:

Oct 6, 2017

Appl. No.:

16/087577

Inventors:

- Singapore, SG
Sethumadhavan Divakaramenon - Lexington MA, US
Christopher J. Francis - Arlington MA, US
Naoki Iwamoto - Brighton MA, US
Genliang Lu - Winchester MA, US
Subramanian Marappan - Acton MA, US
Chandra Vargeese - Schwenksville PA, US
Gregory L. Verdine - Boston MA, US
Hailin Yang - West Roxbury MA, US
Jason Jingxin Zhang - Walpole MA, US

International Classification:

C12N 15/113
A61P 25/14
A61P 21/00
A61K 48/00
A61K 31/7125

Abstract:

Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.

US Patent:

20190249173, Aug 15, 2019

Filed:

May 3, 2017

Appl. No.:

16/098658

Inventors:

Chandra VARGEESE - Cambridge MA, US
Jason Jingxin ZHANG - Cambridge MA, US
Sethumadhavan DIVAKARAMENON - Cambridge MA, US
David Charles Donnell BUTLER - Cambridge MA, US
Genliang LU - Cambridge MA, US
Naoki IWAMOTO - Cambridge MA, US
Hailin YANG - Cambridge MA, US
Subramanian MARAPPAN - Cambridge MA, US
- Singapore, SG

International Classification:

C12N 15/11
A61K 31/7088
A61K 47/54

Abstract:

In some embodiments, the present disclosure pertains to compositions and methods related to delivery of a biologically active agent, wherein the compositions comprise a biologically active agent and a lipid. In various embodiments, the lipid is selected from: lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, docosa-hexaenoic acid (cis-DHA), turbinaric acid and dilinoleyl. In some embodiments, a composition and method are useful for delivery of a biologically active agent to a particular cell or tissue, e.g., a muscle cell or tissue.

US Patent:

20190127733, May 2, 2019

Filed:

Oct 7, 2016

Appl. No.:

15/766578

Inventors:

- Singapore, SG
Sethumadhavan Divakaramenon - Lexington MA, US
Christopher J. Francis - Arlington MA, US
Naoki Iwamoto - Brighton MA, US
Genliang Lu - Winchester MA, US
Subramanian Marappan - Acton MA, US
Chandra Vargeese - Schwenksville PA, US
Gregory L. Verdine - Boston MA, US
Hailin Yang - West Roxbury MA, US
Jason Jingxin Zhang - Walpole MA, US

International Classification:

C12N 15/113
C07H 21/02
C07F 9/59
A61P 27/00
A61K 48/00
A61P 21/00

Abstract:

Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.